{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:23:07Z","timestamp":1760080987558,"version":"3.40.5"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T00:00:00Z","timestamp":1726358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.msard.2024.105894","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T16:54:35Z","timestamp":1726246475000},"page":"105894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The effect of alemtuzumab on neurodegeneration in relapsing-remitting multiple sclerosis: A five-year prospective mono-center study"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-3339","authenticated-orcid":false,"given":"Sofia","family":"Sandgren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Novakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Nordin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemin","family":"Sabir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Axelsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clas","family":"Malmestr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Lycke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2024.105894_bib0002","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/WNO.0000000000000057","article-title":"Retinal nerve fiber layer thickness, brain atrophy, and disability in multiple sclerosis patients","volume":"34","author":"Abalo-Lojo","year":"2014","journal-title":"J. Neuroophthalmol."},{"issue":"14","key":"10.1016\/j.msard.2024.105894_bib0003","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1212\/WNL.0000000000003169","article-title":"Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon \u03b2-1a in MS","volume":"87","author":"Arnold","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2024.105894_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149685","article-title":"The effect of disease-modifying drugs on brain atrophy in relapsing-remitting multiple sclerosis: a meta-analysis","volume":"11","author":"Branger","year":"2016","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.msard.2024.105894_bib0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/WNO.0000000000000802","article-title":"Long-term stability of neuroaxonal structure in alemtuzumab-treated relapsing-remitting multiple sclerosis patients","volume":"40","author":"Chan","year":"2020","journal-title":"J. Neuroophthalmol."},{"issue":"9856","key":"10.1016\/j.msard.2024.105894_bib0006","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.msard.2024.105894_bib0008","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.msard.2024.105894_bib0007","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105894_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102977","article-title":"Persons with suspicious onset of multiple sclerosis but with undetermined diagnosis had persistent lower cognition and reduced quality of life","volume":"52","author":"Constantinescu","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2024.105894_bib0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1148\/radiology.216.3.r00au37672","article-title":"Normal brain development and aging: quantitative analysis at in vivo MR imaging in healthy volunteers","volume":"216","author":"Courchesne","year":"2000","journal-title":"Radiology"},{"issue":"11","key":"10.1016\/j.msard.2024.105894_bib0011","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1002\/eji.200535075","article-title":"Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis","volume":"35","author":"Cox","year":"2005","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2024.105894_bib0014","doi-asserted-by":"crossref","first-page":"e18132","DOI":"10.1371\/journal.pone.0018132","article-title":"Association of retinal and macular damage with brain atrophy in multiple sclerosis","volume":"6","author":"D\u00f6rr","year":"2011","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.msard.2024.105894_bib0012","first-page":"93","article-title":"Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis","volume":"87","author":"De Stefano","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"293","key":"10.1016\/j.msard.2024.105894_bib0013","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/01621459.1961.10482090","article-title":"Multiple comparisons among means","volume":"56","author":"Dunn","year":"1961","journal-title":"J. Am. Stat. Assoc."},{"issue":"4","key":"10.1016\/j.msard.2024.105894_bib0015","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1212\/WNL.54.4.807","article-title":"Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI","volume":"54","author":"Fox","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2024.105894_bib0016","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2014.37","article-title":"Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis","volume":"10","author":"Friese","year":"2014","journal-title":"Nat. Rev. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2024.105894_bib0017","first-page":"1327","article-title":"Age-related total gray matter and white matter changes in normal adult brain. Part I: volumetric MR imaging analysis","volume":"23","author":"Ge","year":"2002","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"4","key":"10.1016\/j.msard.2024.105894_bib0018","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2024.105894_bib0019","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3174\/ajnr.A4665","article-title":"Clinical feasibility of synthetic MRI in multiple sclerosis: a diagnostic and volumetric validation study","volume":"37","author":"Granberg","year":"2016","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"1","key":"10.1016\/j.msard.2024.105894_bib0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/imm.12178","article-title":"Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro","volume":"141","author":"Havari","year":"2014","journal-title":"Immunology"},{"issue":"11","key":"10.1016\/j.msard.2024.105894_bib0021","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","article-title":"Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy","volume":"89","author":"Havrdova","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2024.105894_bib0022","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105894_bib0023","article-title":"Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials","volume":"2014","author":"Lavery","year":"2014","journal-title":"Mult. Scler. Int."},{"key":"10.1016\/j.msard.2024.105894_bib0024","first-page":"453","article-title":"A voxel-based morphometric study of age- and sex-related changes in white matter volume in the normal aging brain","volume":"12","author":"Liu","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"11","key":"10.1016\/j.msard.2024.105894_bib0026","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review","volume":"80","author":"M\u00fcller","year":"2023","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105894_bib0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol."},{"year":"2008","series-title":"Biostatistics: the Bare Essentials","author":"Norman","key":"10.1016\/j.msard.2024.105894_bib0027"},{"issue":"4","key":"10.1016\/j.msard.2024.105894_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194828","article-title":"Searching for neurodegeneration in multiple sclerosis at clinical onset: diagnostic value of biomarkers","volume":"13","author":"Novakova","year":"2018","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.msard.2024.105894_bib0029","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ana.25705","article-title":"Validation of rapid magnetic resonance myelin imaging in multiple sclerosis","volume":"87","author":"Ouellette","year":"2020","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2024.105894_bib0030","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in multiple sclerosis: mechanism of action and beyond","volume":"16","author":"Ruck","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.msard.2024.105894_bib0031","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.53.8.1698","article-title":"Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group","volume":"53","author":"Rudick","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105894_bib0032","first-page":"1","article-title":"A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis","volume":"141","author":"Sandgren","year":"2023","journal-title":"F ront. Neurol"},{"key":"10.1016\/j.msard.2024.105894_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104899","article-title":"Defining progression independent of relapse activity (PIRA) in adult patients with relapsing multiple sclerosis: a systematic review(\u2730)","volume":"78","author":"Sharrad","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2024.105894_bib0034","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ana.24018","article-title":"Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis","volume":"75","author":"Sormani","year":"2014","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.105894_bib0035","doi-asserted-by":"crossref","first-page":"e34823","DOI":"10.1371\/journal.pone.0034823","article-title":"The OSCAR-IB consensus criteria for retinal OCT quality assessment","volume":"7","author":"Tewarie","year":"2012","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.msard.2024.105894_bib0037","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","article-title":"B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis","volume":"30","author":"Thompson","year":"2010","journal-title":"J. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2024.105894_bib0036","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105894_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170018","article-title":"Brain parenchymal fraction in healthy adults-a systematic review of the literature","volume":"12","author":"V\u00e5gberg","year":"2017","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.msard.2024.105894_bib0039","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1136\/jnnp-2021-326164","article-title":"Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy","volume":"92","author":"Wang","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"20","key":"10.1016\/j.msard.2024.105894_bib0001","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.msard.2024.105894_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000971","article-title":"Interferon-\u03b2 is less effective than other drugs in controlling the rate of retinal ganglion cell loss in MS","volume":"8","author":"You","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482400470X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482400470X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T04:30:52Z","timestamp":1732336252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482400470X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":40,"alternative-id":["S221103482400470X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105894","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of alemtuzumab on neurodegeneration in relapsing-remitting multiple sclerosis: A five-year prospective mono-center study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105894"}}